The role of integrins in glioma biology and anti-glioma therapies

Current Pharmaceutical Design

Volumn 17, Issue 23, 2011, Pages 2402-2410

  Tabatabai, Ghazaleh ^a   Tonn, Jörg Christian ^b   Stupp, Roger ^c   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiogenesis; Clinical trials; Glioma; Integrins

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CASPASE 8; CETUXIMAB; CILENGITIDE; ETARACIZUMAB; FIBRONECTIN; GELATINASE A; GELATINASE B; HETERODIMER; INTEGRIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; S 36578; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 6; VITRONECTIN;

ADVANCED CANCER; ANGIOGENESIS; ANOIKIS; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CHEMORADIOTHERAPY; DNA METHYLATION; DRUG ACCUMULATION; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; INTRACELLULAR SIGNALING; MAINTENANCE DRUG DOSE; MEDULLOBLASTOMA; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR INTERACTION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 80053531542     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797249189     Document Type: Review

References (51)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 10: 987-96
2. Stupp R, Hegi M, Mason W, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5- yesar analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66
3. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Disc 2010; 9: 804-20
4. Heynes R. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87
5. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22
6. Schnell O, Krebs B, Wagner E, et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008; 18: 378-86
7. Taga T, Suzuki A, Gonzalez-Gomez I, et al. Alpha vintegrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98: 690-7
8. [Bello L, Francolini M, Marthyn P, et al. Alpha(v) beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001; 49: 380-9, discussion 390
9. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alphaVbeta3 expression with malignant glioma by [18F] Galacto- RGD positron emission tomography. Neuro Oncol 2009; 11: 861-70
10. Worthington JJ, Klementowicz JE, Travis MA. TGFb: a sleeping giant awoken by integrins. Trends Biochem Sci 2011; 36: 47-54
11. Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion. J Neurosurg 2001; 94: 978-84
12. Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009; 11: 747-56.
13. Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(V)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-9
14. Oliveira-Ferrer L, Hauschild J, Fiedler W, et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008; 27: 86
15. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(V) integrin antagonist. Neurosurgery 2001; 48: 151-7
16. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated scheduledependency. Int J Cancer 2009; 124: 2719-27
17. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat Rev Neurosci 2007; 8: 610-22
18. Skuli N, Monferran S, Delmas C, et al. Alphavbeta3/alphavbeta5 integrins-fak-rhob: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 2009; 69: 3308-16
19. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007; 26: 333-9
20. Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6: 421-32
21. Reardon D, Neyns B, Weller M, Tonn JC, Nabors LB and Stupp R. Cilengitide: an RGD-pentapeptide avb3 and avb5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 2011; 7: 339-54
22. Goodman SL, Holzemann G, Sulyok GA, Kessler H. Nanomolar small molecule inhibitors for alphaV(beta)6, alphaV (beta)5, and alphaV(beta)3 integrins. J Med Chem 2002; 45: 1045-51
23. Friedlander M, Theesfeld CL, Sugita M, et al. Involvment of integrins alphaVbeta 3 and alphaVbeta5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93: 9764-9
24. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996; 2: 529-33
25. MacDonald TJ, Stewart CF, Kocak M, et al Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study pbtc-012. J Clin Oncol 2008; 26: 919-24
26. Nabors B, Mikkelsen T, Rosenfeld S, et al. A phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25: 1651-7
27. Gilbert M, Lamborn K, Lassman A, Cloughesy T, Chang S, Lieberman F et al. Tumor tissue delivery of cilengitide fater intravenous administration to patients with recurrent glioblastoma. Preliminary data from NABTC protocol 03-02. Neuro Oncol 2007; 4: 525
28. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 5610-7
29. Fink K, Mikkelsen T, Nabors LB, et al. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a randomized phase IIa study. Proc Am Soc Clin Oncol 2010,
30. Fink K, Mikkelsen T, Nabors LB, et al. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a randomized phase IIa study. J Clin Oncol 28(suppl): 15s, abstract 2010
31. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-8.
32. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 10: 997-1003
33. Nabors L, Mikkelsen T, Batchelor T, et al Nabtt 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2009
34. Nabors L, Mikkelsen T, Batchelor T, et al Nabtt 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) J Clin Oncol 27: 15s, suppl; abstract 2001
35. Fink K, Mikkelsen T, Nabors LB, et al. Long-term effects of cilengitide, a novel integrin inhibitor in recurrent glioblastoma: a randomized phase II a study. J Clin Oncol 28: 15s, 2010 (suppl; abstr 2010)
36. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443-9
37. Stupp R, Van Den Bent MJ, Erridge SC, et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, openlabel, controlled phase III trial (CENTRIC). Proc Am Soc Clin Oncol 2010
38. Stupp R, Van Den Bent MJ, Erridge SC, et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, openlabel, controlled phase III trial (CENTRIC) J Clin Oncol 28: 15s, suppl; abstr TPS152
39. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010; 6: 39-51
40. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alphaVbeta3. Cancer Res 2006; 66: 9673-81
41. Veeravagu A, Liu Z, Niu G, et al. Integrin alphaVbeta3-targeted radioimmunotherapy of gliolbastoma multiforme. Cancer Res. 2008; 15: 7330-9
42. Maubant S, Saint-Dizier D, Boutillon M, et al. Blockade of alphaVbeta3 and alphaVbeta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 2006; 108: 3035-44
43. Plunkett ML, Tel-Tsur Z, Bera M, et al. A novel antiangiogenic/ anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including alpha-5 beta-1 and alpha-v beta-3, leads to increased anti-tumor activity and increased survival in multiple tumor models when combined with chemotherapy. Eur J Cancer 2002; 38(Suppl 7): 79
44. Khalili P, Arakelian A, Chen G, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006; 5: 2271-80
45. Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin alpha5beta1 fu ction with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003; 104: 496-503
46. Cianfrocca ME, Kimmel KA, Gallo J, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist in patients with solid tumours. Br J Cancer. 2006; 94: 1621-6
47. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Rieman I, Weiss EC. Enhanced drug targeting by attachment of an anti alphaV integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 2010; 31: 2388-98
48. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15: 392-400
49. Weller M, Reardon D, Nabors B, Stupp R. Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med 2009; 15: 726
50. Legler DF, Wiedle G, Ross FP, Imhof BA. Superactivation of integrin alphaVbeta3 by low antagonist concentrations. J Cell Sci 2001; 114: 1545-53
51. Weis SM, Stupack DG, Cheresh DA. Agonizing integrin antagonists? Cancer Cell 2009; 15: 359-61.